In vitro screening for angiostatic potential of herbal chemicals

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 12, 2010, Pages 6658-6664

  Cao, Liming ^a,b   Liu, Huanming ^a   Lam, Dennis Shun Chiu ^a   Yam, Gary Hin Fai ^a   Pang, Chi Pui ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Xiamen Eye Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR; EPIGALLOCATECHIN GALLATE; FOCAL ADHESION KINASE; GAMBOGIC ACID; HERBACEOUS AGENT; ISOLIQUIRITIGENIN; RESVERATROL; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL ASSAY; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME ACTIVATION; GARCINIA HANBURYI; GLYCYRRHIZA; GRAPE; GROWTH INHIBITION; HERBAL MEDICINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDICINAL PLANT; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA CELL; SIGNAL TRANSDUCTION; TEA; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOTTING, WESTERN; CATECHIN; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHALCONES; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE PROTEINS; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; NERVE GROWTH FACTORS; PLANT PREPARATIONS; RETINAL PIGMENT EPITHELIUM; SERPINS; STILBENES; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XANTHONES;

EID: 79955943748     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5524     Document Type: Article

References (54)

1. Regional Publication, Western Pacific Series. No. 2. Compiled by the Institute of Chinese Materia Medica, China Academy of Traditional Chinese Medicine. Manila, The Philippines: World Health Organization; 1989.
2. Bruno JJ, Ellis JJ. Herbal use among US elderly: 2002 National Health Interview Survey. Ann Pharmacother. 2005;39:643-648.
3. Bent S, Ko R. Commonly used herbal medicines in the United States: a review. Am J Med. 2004;116:478-485.
4. De Smet P. Herbal medicine in Europe-relaxing regulatory standards. N Engl J Med. 2005;352:1176-1178.
5. Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006;10:159-170.
6. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol. 2007;2:251-275.
7. Drevs J, Schneider V. The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis. J Intern Med. 2006;260:517-529.
8. Ardavanis A, Doufexis D, Kountourakis P, et al. Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study. BMC Cancer. 2009;9:338.
9. Bressler NM. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology. 2009;116:S15-S23.
10. Cohen SY. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina. 2009;29:1062-1066.
11. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol. 2009;5:610-620.
12. Tamaskar I, Pili R. Update on novel agents in renal cell carcinoma. Expert Rev Anticancer Ther. 2009;9:1817-1827.
13. Koutras AK, Fountzilas G, Makatsoris T, Peroukides S, Kalofonos HP. Bevacizumab in the treatment of breast cancer. Cancer Treat Rev. 2010;36:75-82.
14. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene. 1997;15:2169-2177.
15. Sen CK, Gordillo GM, Khanna S, Roy S. Micromanaging vascular biology: tiny microRNAs play big band. J Vasc Res. 2009;46:527-540.
16. Lamalice L, Houle F, Huot J. Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF. J Biol Chem. 2006;281:34009-34020.
17. Greenberg JI, Cheresh DA. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opin Biol Ther. 2009;9:1347-1356.
18. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009;6:569-579.
19. Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs. 2009;23:289-304.
20. Pepper MS, Montesano R. Proteolytic balance and capillary morphogenesis. Cell Differ Dev. 1990;32:319-327.
21. Lampugnani MG. Cell migration into a wounded area in vitro. Methods Mol Biol. 1999;96:177-182.
22. Azar DT, Casanova FH, Mimura T, et al. Corneal epithelial MT1-MMP inhibits vascular endothelial cell proliferation and migration. Cornea. 2010;29:321-330.
23. Chia JS, Du JL, Hsu WB, Sun A, Chiang CP, Wang WB. Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid. BMC Cancer. 2010;10:175.
24. Daud NH, Aung CS, Hewavitharana AK, et al. Mango extracts and the mango component mangiferin promote endothelial cell migration. J Agric Food Chem. 2010;58:5181-5186.
25. Kwak DH, Kim JK, Kim JY, et al. Anti-angiogenic activities of Cnidium officinale Makino and Tabanus bovinus. J Ethnopharmacol. 2002;81:373-379.
26. Wang S, Zheng Z, Weng Y, et al. Angiogenesis and anti-angiogenesis activity of Chinese medicinal herbal extracts. Life Sci. 2004;74:2467-2478.
27. Kumar S, Sharma A, Madan B, Singhal V, Ghosh B. Isoliquiritigenin inhibits IκB kinase activity and ROS generation to block TNF-αinduced expression of cell adhesion molecules on human endothelial cells. Biochem Pharmacol. 2007;73:1602-1612.
28. Haraguchi H, Ishikawa H, Mizutani K, Tamura Y, Kinoshita T. Antioxidative and superoxide scavenging activities of retrochalcones in Glycyrrhiza inflata. Bioorg Med Chem. 1998;6:339-347.
29. Maggiolini M, Statti G, Vivacqua A, et al. Estrogenic and antiproliferative activities of isoliquiritigenin in MCF7 breast cancer cells. J Steroid Biochem Mol Biol. 2002;82:315-322.
30. Ii T, Satomi Y, Katoh D, et al. Induction of cell cycle arrest and p21(CIP1/WAF1) expression in human lung cancer cells by isoliquiritigenin. Cancer Lett. 2004;207:27-35.
31. Tawata M, Aida K, Noguchi T, et al. Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice. Eur J Pharmacol. 1992;212:87-92.
32. Aida K, Tawata M, Shindo H, et al. Isoliquiritigenin: a new aldose reductase inhibitor from glycyrrhizae radix. Planta Med. 1990;56:254-248.
33. Hsu YL, Kuo PL, Lin CC. Isoliquiritigenin induces apoptosis and cell cycle arrest through p53-dependent pathway in Hep G2 cells. Life Sci. 2005;77:279-292.
34. Park I, Park KK, Park JH, Chung WY. Isoliquiritigenin induces G2 and M phase arrest by inducing DNA damage and by inhibiting the metaphase/anaphase transition. Cancer Lett. 2009;277:174-181.
35. Yamamoto S, Aizu E, Jiang H, et al. The potent anti-tumor-promoting agent isoliquiritigenin. Carcinogenesis. 1991;12:317-323.
36. Kobayashi S, Miyamoto T, Kimura I, Kimura M. Inhibitory effect of isoliquiritin, a compound in licorice root, on angiogenesis in vivo and tube formation in vitro. Biol Pharm Bull. 1995;18:1382-1386.
37. Kwon GT, Cho HJ, Chung WY, Park KK, Moon A, Park JH. Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. J Nutr Biochem. 2009;20:663-676.
38. Kang SW, Choi JS, Choi YJ, et al. Licorice isoliquiritigenin dampens angiogenic activity via inhibition of MAPK-responsive signaling pathways leading to induction of matrix metalloproteinases. J Nutr Biochem. 2010;21:55-65.
39. Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med. 2002;8:330-334.
40. Mukhtar H, Ahmad N. Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr. 2000;71:1698S-1702S.
41. Crespy V, Williamson G. A review of the health effects of green tea catechins in in vivo animal models. J Nutr. 2004;134:3431S-3440S.
42. Cooper R, Morre DJ, Morre DM. Medicinal benefits of green tea, II: review of anticancer properties. J Altern Complement Med. 2005;11:639-652.
43. Oak MH, El Bedoui J, Schini-Kerth VB. Antiangiogenic properties of natural polyphenols from red wine and green tea. J Nutr Biochem. 2005;16:1-8.
44. Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature. 1999;398:381.
45. Saito Y, Hasebe-Takenaka Y, Ueda T, et al. Effects of green tea fractions on oxygen-induced retinal neovascularization in the neonatal rat. J Clin Biochem Nutr. 2007;41:43-49.
46. Koh SH, Kim SH, Kwon H, et al. Phosphatidylinositol-3 kinase/Akt and GSK-3 mediated cytoprotective effect of epigallocatechin gallate on oxidative stress-injured neuronal-differentiated N18D3 cells. Neurotoxicology. 2004;25:793-802.
47. Zhang T, Yang D, Fan Y, Xie P, Li H. Epigallocatechin-3-gallate enhances ischemia/reperfusion-induced apoptosis in human umbilical vein endothelial cells via AKT and MAPK pathways. Apoptosis. 2009;14:1245-1254.
48. Delmas D, Rebe C, Lacour S, et al. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem. 2003;278:41482-41490.
49. Huang C, Ma WY, Goranson A, Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis. 1999;20:237-242.
50. Athar M, Back JH, Tang X, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol. 2007;224:274-283.
51. Kimura Y, Okuda H. Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr. 2001;131:1844-1849.
52. Tseng SH, Lin SM, Chen JC, et al. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res. 2004;10:2190-2202.
53. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008;28:1053-1060.
54. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. 2009;93:452-456.